A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.
about
The Light and Shadow of Senescence and Inflammation in Cardiovascular Pathology and Regenerative Medicine.Vascular Senescence in Cardiovascular and Metabolic Diseases.Non-Cell Autonomous Effects of the Senescence-Associated Secretory Phenotype in Cancer Therapy.Improved Dose-Response Relationship of (+)-Discodermolide-Taxol Hybrid Congeners.Ageing, Cellular Senescence and Neurodegenerative Disease
P2860
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.
@ast
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.
@en
type
label
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.
@ast
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.
@en
prefLabel
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.
@ast
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.
@en
P2093
P2860
P1433
P1476
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.
@en
P2093
Alfred Adomako
Alicia Rodriguez-Gabin
Hayley M McDaid
Leleesha Samaraweera
P2860
P2888
P356
10.1038/S41598-017-01964-1
P407
P577
2017-05-15T00:00:00Z
P6179
1085378951